Design, synthesis, and activity evaluation of selective CDK9 inhibitors containing indazole fragments
- 10 October 2025
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 166, 109083
Abstract
No abstract availableKeywords
Funding Information
- Shenyang Pharmaceutical University (202410163050)
- National Natural Science Foundation of China (22177079, 22477085)
This publication has 19 references indexed in Scilit:
- Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In VivoJournal of Medicinal Chemistry, 2025
- Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast CancerJournal of Medicinal Chemistry, 2024
- Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity EvaluationJournal of Medicinal Chemistry, 2024
- A retrospective-prospective review of Suzuki–Miyaura reaction: From cross-coupling reaction to pharmaceutical industry applicationsPolyhedron, 2022
- Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementJournal of Medicinal Chemistry, 2021
- New Insights into CDK Regulators: Novel Opportunities for Cancer TherapyTrends in Cell Biology, 2021
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- The 25th Anniversary of the Buchwald–Hartwig Amination: Development, Applications, and OutlookOrganic Process Research & Development, 2019
- Targeting CDK9 Reactivates Epigenetically Silenced Genes in CancerCell, 2018
- Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitorEuropean Journal of Medicinal Chemistry, 2018